Provided by Tiger Trade Technology Pte. Ltd.

Alexander's

246.11
-3.6600-1.47%
Post-market: 246.110.00000.00%19:26 EDT
Volume:30.48K
Turnover:7.53M
Market Cap:1.26B
PE:61.37
High:249.78
Open:249.59
Low:245.00
Close:249.77
52wk High:260.84
52wk Low:201.28
Shares:5.11M
Float Shares:2.13M
Volume Ratio:1.09
T/O Rate:1.43%
Dividend:18.01
Dividend Rate:7.32%
EPS(TTM):4.01
EPS(LYR):5.50
ROE:16.21%
ROA:3.09%
PB:13.85
PE(LYR):44.78

Loading ...

BRIEF-Alexander’S Completes Sale Of Rego Park I

Reuters
·
May 29

Alexander’s Completes Sale of Rego Park I

THOMSON REUTERS
·
May 29

Alexander’s completes sale of Rego Park I property to Northwell Health for $235.5 million

Reuters
·
May 29

Alexander’s shareholders approve 2026 omnibus stock plan at annual meeting

Reuters
·
May 22

Analysts Conflicted on These Healthcare Names: Senti Biosciences (SNTI), ALX Oncology Holdings (ALXO) and Argenx Se (ARGX)

TIPRANKS
·
May 18

Analysts’ Opinions Are Mixed on These Healthcare Stocks: ALX Oncology Holdings (ALXO) and Heron Therapeutics (HRTX)

TIPRANKS
·
May 12

ALX Oncology Holdings Q1 Adj. EPS $(0.15) Beats $(0.22) Estimate

Benzinga
·
May 08

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
May 08

ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

GlobeNewswire
·
May 07

BRIEF-Alexander's Q1 Adjusted FFO Per Share USD 2.6

Reuters
·
May 04

Alexander’s Announces First Quarter Financial Results

THOMSON REUTERS
·
May 04

Alexander's Q1 Adjusted Ffo per Share USD 2.6

THOMSON REUTERS
·
May 04

Alexander's Q1 EPS USD 0.91

THOMSON REUTERS
·
May 04

Alexander's Q1 Adjusted Ffo USD 13.364 Million

THOMSON REUTERS
·
May 04

Earnings Flash (ALX) Alexander's Posts Q1 Non-GAAP FFO $2.60 a Share, vs. FactSet Est of $2.82

MT Newswires Live
·
May 04

Alexander's Q1 FY26 net income drops to $4.66 million; revenue slips to $53.41 million

Reuters
·
May 04

Alexander's Inc expected to post a share - Earnings Preview

Reuters
·
May 01

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

GlobeNewswire
·
Apr 30

Alexander's declares quarterly dividend of $4.5 per share

Reuters
·
Apr 29

Earning Preview: Alexander's Q1 revenue is expected to decrease by 3.06%, and institutional views are Neutral-to-Cautious

Earnings Agent
·
Apr 27